Table of Contents
1. Preface
2. Assumptions and Research Methodology
3. Executive Summary: Global Market
4. Market Overview
5. Market Outlook
6. Global Market Analysis and Forecasts, by Drug Class
- 6.1. Corticosteroids
- 6.2. PDE4 Inhibitors
- 6.3. Biologics
- 6.4. Skin Barrier Emollients
- 6.5. CNI Immunosuppressants
- 6.6. Others
7. Global Market Analysis and Forecasts, by Distribution Channel
- 7.1. Hospital Pharmacies
- 7.2. Retail Pharmacies
- 7.3. Online Pharmacies
8. Global Market Analysis and Forecasts, by Region
- 8.1. North America
- 8.2. Europe
- 8.3. Asia Pacific
- 8.4. Latin America
- 8.5. Middle East & Africa
9. North America Market Analysis and Forecast
10. Europe Market Analysis and Forecast
11. Asia Pacific Market Analysis and Forecast
12. Latin America Market Analysis and Forecast
13. Middle East & Africa Market Analysis and Forecast
14. Competitive Landscape
- 14.1. Mylan N.V.
- 14.2. Pfizer, Inc.
- 14.3. LEO Pharma A/S
- 14.4. Teva Pharmaceutical Industries Ltd
- 14.5. Sanofi
- 14.6. Novartis AG
List of Tables
Table 01: Global Market Value (US$ Mn) Forecast, by Drug Class, 2024 to 2034
Table 02: Global Market Value (US$ Mn) Forecast, by Distribution Channel, 2024 to 2034
Table 03: Global Market Value (US$ Mn) Forecast, by Region, 2024 to 2034
Table 04: North America Market Value (US$ Mn) Forecast, by Country, 2024 to 2034
Table 05: North America Value (US$ Mn) Forecast, by Drug Class, 2024 to 2034
Table 06: North America Market Value (US$ Mn) Forecast, by Distribution Channel, 2024 to 2034
Table 07: Europe Market Value (US$ Mn) Forecast, by Country/Sub-region, 2024 to 2034
Table 08: Europe Value (US$ Mn) Forecast, by Drug Class, 2024 to 2034
Table 09: Europe Market Value (US$ Mn) Forecast, by Distribution Channel, 2024 to 2034
Table 10: Asia Pacific Market Value (US$ Mn) Forecast, by Country/Sub-region, 2024 to 2034
Table 11: Asia Pacific Value (US$ Mn) Forecast, by Drug Class, 2024 to 2034
Table 12: Asia Pacific Market Value (US$ Mn) Forecast, by Distribution Channel, 2024 to 2034
Table 13: Latin America Market Value (US$ Mn) Forecast, by Country/Sub-region, 2024 to 2034
Table 14: Latin America Value (US$ Mn) Forecast, by Drug Class, 2024 to 2034
Table 15: Latin America Market Value (US$ Mn) Forecast, by Distribution Channel, 2024 to 2034
Table 16: Middle East & Africa Market Value (US$ Mn) Forecast, by Country/Sub-region, 2024 to 2034
Table 17: Middle East & Africa Value (US$ Mn) Forecast, by Drug Class, 2024 to 2034
Table 18: Middle East & Africa Market Value (US$ Mn) Forecast, by Distribution Channel, 2024 to 2034
List of Figures
Figure 01: Global Market Snapshot
Figure 02: Global Market Value (US$ Mn) and Distribution, by Region, 2024 and 2029
Figure 03: Global Market Value (US$ Mn) Forecast, 2024 to 2034
Figure 04: Global Market Value Share (%), by Drug Class (2024)
Figure 05: Global Market Value Share (%), by Distribution Channel (2024)
Figure 06: Global Market Value Share (%), by Region (2024)
Figure 07: Global Market Value Share Analysis, by Drug Class, 2024 and 2029
Figure 08: Global Market Attractiveness, by Drug Class, 2024 to 2029
Figure 09: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Corticosteroids, 2024 to 2034
Figure 10: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by PDE4 Inhibitors, 2024 to 2034
Figure 11: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Biologics, 2024 to 2034
Figure 12: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Skin Barrier Emollients, 2024 to 2034
Figure 13: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by CNI Immunosuppressants, 2024 to 2034
Figure 14: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2024 to 2034
Figure 15: Global Market Value Share (%), by Distribution Channel, 2024 and 2029
Figure 16: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2024 to 2034
Figure 17: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Retail Pharmacies, 2024 to 2034
Figure 18: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Online Pharmacies, 2024 to 2034
Figure 19: Global Market Attractiveness, by Distribution Channel, 2024 to 2029
Figure 20: Global Market Value Share Analysis, by Region, 2024 and 2029
Figure 21: Global Market Attractiveness, by Region, 2024 to 2029
Figure 22: North America Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2024 to 2034
Figure 23: North America Market Value Share (%), by Country, 2024 and 2029
Figure 24: North America Market Attractiveness, by Country, 2024 to 2029
Figure 25: North America Market Value Share (%), by Drug Class, 2024 and 2029
Figure 26: North America Market Attractiveness, by Drug Class, 2024 to 2029
Figure 27: North America Market Value Share (%), by Distribution Channel, 2024 and 2029
Figure 28: North America Market Attractiveness, by Distribution Channel, 2024 to 2029
Figure 29: Europe Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2024 to 2034
Figure 30: Europe Market Value Share (%), by Country/Sub-region, 2024 and 2029
Figure 31: Europe Market Attractiveness, by Country/Sub-region, 2024 to 2029
Figure 32: Europe Market Value Share (%), by Drug Class, 2024 and 2029
Figure 33: Europe Market Attractiveness, by Drug Class, 2024 to 2029
Figure 34: Europe Market Value Share (%), by Distribution Channel, 2024 and 2029
Figure 35: Europe Market Attractiveness, by Distribution Channel, 2024 to 2029
Figure 36: Asia Pacific Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2024 to 2034
Figure 37: Asia Pacific Market Value Share (%), by Country/Sub-region, 2024 and 2029
Figure 38: Asia Pacific Market Attractiveness, by Country/Sub-region, 2024 to 2029
Figure 39: Asia Pacific Market Value Share (%), by Drug Class, 2024 and 2029
Figure 40: Asia Pacific Market Attractiveness, by Drug Class, 2024 to 2029
Figure 41: Asia Pacific Market Value Share (%), by Distribution Channel, 2024 and 2029
Figure 42: Asia Pacific Market Attractiveness, by Distribution Channel, 2024 to 2029
Figure 43: Latin America Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2020 to 2027
Figure 44: Latin America Market Value Share (%), by Country/Sub-region 2024 and 2029
Figure 45: Latin America Market Attractiveness, by Country/Sub-region, 2024 to 2029
Figure 46: Latin America Market Value Share (%), by Drug Class, 2024 and 2029
Figure 47: Latin America Market Attractiveness, by Drug Class, 2024 to 2029
Figure 48: Latin America Market Value Share (%), by Distribution Channel, 2024 and 2029
Figure 49: Latin America Market Attractiveness, by Distribution Channel, 2024 to 2029
Figure 50: Middle East & Africa Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2024 to 2034
Figure 51: Middle East & Africa Market Value Share (%), by Country/Sub-region 2024 and 2034
Figure 52: Middle East & Africa Market Attractiveness, by Country/Sub-region, 2024 to 2034
Figure 53: Middle East & Africa Market Value Share (%), by Drug Class, 2024 and 2034
Figure 54: Middle East & Africa Market Attractiveness, by Drug Class, 2024 to 2034
Figure 55: Middle East & Africa Market Value Share (%), by Distribution Channel, 2024 and 2034
Figure 56: Middle East & Africa Market Attractiveness, by Distribution Channel, 2024 to 2034
Figure 57: Mylan N.V. Revenue (US$ Mn) and Y-o-Y Growth (%), 2019 to 2023
Figure 58: Mylan N.V. R&D Expenses (US$ Mn), 2018 to 2020
Figure 59: Mylan N.V. Breakdown of Net Sales (%), by Region, 2020
Figure 60: Mylan N.V. Breakdown of Net Sales (%), by Business Segment, 2020
Figure 61: Pfizer, Inc. Breakdown of Net Sales, by Region, 2020
Figure 62: Pfizer, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2015 to 2020
Figure 63: Pfizer, Inc. R&D Expenses (US$ Mn), 2018 to 2020
Figure 64: LEO Pharma A/S Breakdown of Net Sales, by Region (2018)
Figure 65: LEO Pharma A/S Breakdown of Net Sales, by Therapeutic Area (2018)
Figure 66: LEO Pharma A/S Revenue (US$ Mn) & Y-o-Y Growth (%), 2016 to 2020
Figure 67: LEO Pharma A/S R&D Expenses (US$ Mn), 2018 to 2020
Figure 68: Sanofi Revenue (US$ Bn), 2017 to 2020
Figure 69: Sanofi Regional Sales Breakdown (%), 2020
Figure 70: Novartis AG Breakdown of Net Sales, by Region, 2020
Figure 71: Novartis AG Breakdown of Net Sales, by Business Segment, 2020
Figure 72: Novartis AG Revenue (US$ Bn) and Y-o-Y Growth (%), 2017 to 2020
Figure 73: Novartis AG R&D Expenses (US$ Mn), 2018 to 2020
Figure 74: Teva Pharmaceutical Revenue (US$ Mn) & Y-o-Y Growth (%), 2016 to 2020
Figure 75: Teva Pharmaceutical R&D Expenses (US$ Mn), 2018 to 2020
Figure 76: Teva Pharmaceutical Breakdown of Net Sales, by Region, 2020
Figure 77: Teva Pharmaceutical Breakdown of Net Sales, (Overall Company Level), 2020
Who worked on this report
Preview the report firsthand - request a free sample
Free SampleGet the brochure for pricing and purchase details
Download PDF